Therapy of Myelodysplastic Syndrome (MDS) with azacitidine given in combination with etanercept: A phase II study

被引：0
|
作者：
Holsinger, Aaron L. [1 ,2 ]
Ramakrishnan, Aravind [1 ,2 ]
Storer, Barry [1 ,2 ]
Becker, Pamela S. [1 ,2 ]
Petersdorf, Stephen [1 ,2 ]
Deeig, H. Joachim [1 ,2 ]
Scott, Bart L. [1 ,2 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1452
引用
收藏
页码：435A / 435A
页数：1
相关论文
共 50 条
  • [31] Therapy of early stage myelodysplastic syndrome (MDS) with anti-thymocyte globulin (ATG) and etanercept
    Scott, Bart L.
    Holsinger, Aaron L.
    Ramakrishnan, Aaravind
    Storer, Barry
    Becker, Pamela S.
    Petersdorf, Stephen
    Deeg, H. Joachim
    BLOOD, 2007, 110 (11) : 438A - 438A
  • [32] Initial Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndrome and Myelodysplastic/Myeloproliferative Neoplasm with FLT3 or CBL Mutations
    Abuasab, Tareq
    Jabbour, Elias J.
    Short, Nicholas J.
    Konopleva, Marina
    Chien, Kelly S.
    Mohamed, Shehab Fareed
    Daver, Naval
    Kanagal-Shamanna, Rashmi
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Montalban-Bravo, Guillermo
    BLOOD, 2021, 138
  • [33] Preliminary results from a phase I study of Revlimid® (Lenalidomide) in combination with Vidaza® (Azacitidine) in patients with advanced myelodysplastic syndromes (MDS)
    Sekeres, Mikkael A.
    List, Alan
    Cuthbertson, David
    Paquette, Ronald
    Loughran, Thomas
    Maciejewski, Jaroslaw P.
    BLOOD, 2007, 110 (11) : 437A - 437A
  • [34] Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
    Sekeres, Mikkael A.
    List, Alan F.
    Cuthbertson, David
    Paquette, Ronald
    Latham, Deborah
    Afable, Manual
    Paulic, Katarina
    Loughran, Thomas P., Jr.
    Maciejewski, Jaroslaw P.
    BLOOD, 2008, 112 (11) : 88 - 89
  • [35] A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)
    Palmisiano, Neil
    Jeschke, Grace
    Wilde, Lindsay
    Leiby, Benjamin E.
    Alpdogan, Onder
    Carabasi, Matthew
    Filicko-O'Hara, Joanne
    Gaballa, Sameh
    Grosso, Dolores
    Klumpp, Thomas R.
    Outschoorn, Ubaldo Martinez
    Wagner, John L.
    Carroll, Martin
    Porcu, Pierluigi
    Flomenberg, Neal
    Perl, Alexander E.
    Kasner, Margaret
    BLOOD, 2017, 130
  • [36] A Case Of Azacitidine Induced Interstitial Pneumonitis In A Patient With Myelodysplastic Syndrome (mds)
    Patel, V.
    Sarkar, S.
    Cervellione, K. L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [37] Five-Year Follow up Results of Phase II Clinical Trial Evaluating Ruxolitinib (RUX) and Azacitidine (AZA) Combination Therapy in Patients (pts) with Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)
    Arora, Sankalp
    Senapati, Jayastu
    Pemmaraju, Naveen
    Bose, Prithviraj
    Masarova, Lucia
    Montalban-Bravo, Guillermo
    Maiti, Abhishek
    Kadia, Tapan M.
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    Daver, Naval
    BLOOD, 2023, 142
  • [38] A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure
    Ong, Faustine
    Garcia-Manero, Guillermo
    Montalban-Bravo, Guillermo
    Alvarado, Yesid
    Ohanian, Maro
    Konopleva, Marina
    Jabbour, Elias
    Jain, Nitin
    Borthakur, Gautam
    DiNardo, Courtney D.
    Daver, Naval
    Issa, Ghayas C.
    Sasaki, Koji
    Chien, Kelly S.
    Takahashi, Koichi
    Andreeff, Michael
    Muftuoglu, Muharrem
    Delumpa, Ricardo
    Mayor, Ejiroghene
    Loiselle, Christopher
    Waller, Lourdes
    Banks, Glenda
    Kantarjian, Hagop
    Cortes, Jorge E.
    Short, Nicholas
    BLOOD, 2022, 140 : 6206 - 6208
  • [39] Initial Results of a Phase I/II Study of Venetoclax in Combination with Azacitidine in Treatment-Naive and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
    Morita, Kiyomi
    Naqvi, Kiran
    Montalban, Guillermo
    Thompson, Philip A.
    Takahashi, Koichi
    Alvarado, Yesid
    Jabbour, Elias
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2020, 136
  • [40] Azacitidine for Treatment of Therapy Related Myelodysplastic Syndrome
    Komrokji, Rami S.
    Al Ali, Najla H.
    Alrawi, E.
    Padron, Eric
    Perkins, Janelle
    Field, Teresa
    Lancet, Jeffrey E.
    List, Alan F.
    BLOOD, 2011, 118 (21) : 745 - 746
12345